9
Total deals
$11.2B
Total value
$1.9B
Avg deal
$8.4B
Largest
| # | Acquired | Date | Type | Status | Price | |
|---|---|---|---|---|---|---|
| 1 |
LogicBio Therapeutics
LogicBio develops gene therapy vectors for previously incurable genetic and infe…
|
2022-10-03 | Acquisition | Complete | $70.0M | Deal → |
| 2 |
Portola Pharmaceuticals
Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascul…
|
2020-05-05 | Acquisition | Complete | $1.4B | Deal → |
| 3 |
Achillion Pharmaceuticals
A biopharmaceutical company dedicated to transforming the lives of patients and …
|
2019-10-16 | Acquisition | Complete | — | Deal → |
| 4 |
Syntimmune
Syntimmune develops differentiated drug candidates in a wide range of autoimmune…
|
2018-09-26 | Acquisition | Complete | $1.2B | Deal → |
| 5 |
Wilson Therapeutics
Wilson Therapeutics focuses on developing novel therapies addressing unmet medic…
|
2018-04-11 | Acquisition | Complete | — | Deal → |
| 6 |
Synageva BioPharma
Synageva, a biopharmaceutical company, develops and commercializes novel, next g…
|
2015-05-06 | Acquisition | Complete | $8.4B | Deal → |
| 7 |
Enobia Pharma
Enobia Pharma develops therapies for the treatment of serious genetic bone disor…
|
2011-12-29 | Acquisition | Complete | — | Deal → |
| 8 |
Taligen Therapeutics
Taligen Therapeutics is focused on the R&D of novel protein therapeutics for the…
|
2011-01-31 | Acquisition | Complete | $111.0M | Deal → |
| 9 |
P
Prolifaron
Prolifaron developing therapeutic antibodies addressing multiple diseases, inclu…
|
2000-09-25 | Acquisition | Complete | $41.0M | Deal → |